Combining SFRP3 suppression with chemotherapy agent vincristine was more effective at reducing alveolar rhabdomyosarcoma cell line growth than either treatment alone, and the addition of vincristine ablated tumorigenesis in the conditional murine xenograft. The gene discussed is FRZB; the disease is rhabdomyosarcoma.